RE-LIVER
Bottom-up reconstitution of a biomimetic bioartificial liver
| Coordinatore | UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 5˙377˙150 € |
| EC contributo | 4˙234˙877 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-2 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-07-01 - 2015-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
IT (PISA) | coordinator | 824˙999.00 |
| 2 |
MEDICYTE GMBH
Organization address
address: Im Neuenheimer Feld 581 contact info |
DE (Heidelberg) | participant | 1˙738˙180.00 |
| 3 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 763˙152.00 |
| 4 |
THE ELECTROSPINNING COMPANY LTD
Organization address
address: WATERMARK WAY 10 contact info |
UK (HERTFORD) | participant | 559˙356.00 |
| 5 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 349˙190.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The liver, by way of its central role in both endogenous and exogenous metabolism, is one of the most well-studied organs in the human body. Hepatic tissue and its derivatives have a wide range of in-vivo and in-vitro applications from whole organ or partial lobe transplant, bioartificial ex-vivo devices, treatment of metabolic disorders to toxicology, drug metabolism and tissue regeneration. On the one hand, suitable donor livers for solid organ transplant are in short supply, while chronic liver diseases are on the increase both in Europe and world-wide. On the other hand, in-vitro and ex-vivo technologies for recapitulating liver function still fall short of reliability, consistency and predictivity, precluding many commercial applications. There is a dire need for innovative and reproducible methods for developing functional bioartificial livers or portions of liver which can be easily transplanted or reliably integrated into extracorporeal devices, essential for treating acute liver failure and other metabolic liver disorders. To avoid the risks and complications associated with animal/human matrices, yet furnish a reliable and reproducible 3D microarchitecture capable of maintaining the detoxification and metabolic functions of healthy human liver, our aim is to fabricate a novel hepatic lobuli ECM replica seeded with stable human hepatocytes and endothelial cells using the human liver as a design template through a bottom up approach. These cell-containing bioartificial constructs will be developed and characterized in vitro to assess metabolic function, protein production and angiogenic potential. They will then be implanted in animal models through minimally invasive techniques as a solid organ transplant alternative to recombinant Factor VIII-based therapy for patients with haemophilia A.'